SL PHARM(002038)2025-03-26 10:30Financial Performance Expectations - The company expects a net profit loss of 32 million yuan for 2024, a decrease of 107.68% compared to the previous year's profit of 52 million yuan[3]. - Total profit is projected to be a loss of 62 million yuan, down 113.34% from a profit of 82 million yuan in the same period last year[3]. - The net profit after deducting non-recurring gains and losses is expected to be 120 million yuan, a decrease of 48.63% from 100 million yuan in the previous year[3]. - The basic earnings per share is projected to be a loss of 0.03 yuan per share, compared to a profit of 0.05 yuan per share last year[3]. Reasons for Profit Decline - The significant decline in net profit is primarily due to a decrease in product prices leading to reduced operating income[5]. - Fluctuations in the stock prices of held trading financial assets resulted in a net profit decrease of 178 million yuan, contrasting with a profit increase of 197 million yuan from stock price fluctuations in 2023[5]. Communication and Reporting - The company has communicated with its accounting firm regarding the performance forecast, and there are no significant discrepancies[4]. - The financial data provided is preliminary and will be detailed in the 2024 annual report, urging investors to exercise caution[6].